MCT and Capsaicin Provocation Challenge in Diagnosis of Chronic Cough
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03363698|
Recruitment Status : Recruiting
First Posted : December 6, 2017
Last Update Posted : December 6, 2017
The aim of the study is to assess the prevalence of bronchial hyperresponsiveness (BHR) in non-smoking adults with chronic cough and the prevalence of BHR in patients with upper airway cough syndrome (UACS) and gastroesophageal reflux disease (GERD), to evaluate the relationship between BHR and cough reflex sensitivity, to assess the diagnostic accuracy of methacholine challenge test (MCT) in cough variant asthma (CVA) with special regard to its discriminating cut off value between CVA and other causes of chronic cough, particularly GERD, to estimate prognostic value of BHR, fractional exhaled nitric oxide (FeNO) and induced sputum eosinophil count in predicting response to asthma treatment.
Patients diagnosed with a chronic cough will undergo the standard diagnostic work-up recommended by experts for patients with a chronic cough, including methacholine challenge test (MCT) and an at least 4-week period of causal treatment. Patients with BHR in MCT will be treated with - in first step B2-agonist and inhaled corticosteroid (ICS) for at least 4 weeks, if improvement is not significant in next steps with leukotriene receptor antagonist (LTRA) or systemic corticosteroid. A good treatment response, evaluated by visual analogue scale (VAS), Leicester Cough Questionnaire (LCQ) and cough challenge will confirm the diagnosis of the disease. A statistical analysis will consist of the frequency of BHR in a chronic cough, correlation between the results of MCT and cough reflex sensitivity in capsaicin inhalation test and cut-off point for MCT to discriminate asthma from other causes of a chronic cough.
|Condition or disease||Intervention/treatment|
|Cough Cough Variant Asthma Upper-Airway Cough Syndrome GERD Allergic Rhinitis||Other: Cough variant asthma treatment|
The present study has the following objectives:
- to assess the prevalence of BHR in non-smoking adults with a chronic cough,
- to assess the prevalence of BHR in patients with UACS and GERD,
- to evaluate the relationship between BHR and cough reflex sensitivity,
- to assess the diagnostic accuracy of MCT in CVA with special regard to its discriminating value between CVA and other causes of a chronic cough, particularly GERD,
- to estimate prognostic value of BHR, fractional exhaled nitric oxide (FeNO) and induced sputum eosinophil count in predicting response to asthma treatment.
The investigated group will consist of 80 non-smoking adults (18-75 years old), who are not treated with angiotensin-converting enzyme inhibitors, with no signs of respiratory infection within six weeks prior to enrolment, with a normal chest radiograph and who are referred to the hospital due to a cough lasting at least eight weeks.
After obtaining an informed consent, the diagnostic approach of the most common causes of chronic cough will be performed: a medical history, physical examination, chest radiograph, in some cases chest computed tomography, pulmonary function tests (spirometry, fractional exhaled nitric oxide, methacholine challenge test), laboratory tests (total immunoglobulin E concentration, complete blood count), skin prick tests, induced sputum cell count, computed tomography of the paranasal sinuses and ENT consultation, 24-hour impedance with pH monitoring, videolaryngoscopy and cough challenge with capsaicin.
The cough severity will be assessed twice (on admission and after six weeks of causal treatment) using the Visual Analogue Scale (VAS), the Polish version of the Leicester Cough Questionnaire (LCQ) and the capsaicin inhalation cough challenge.
If MCT result is positive, CVA will be assumed the cause of a chronic cough and treatment with an inhaled steroid combined with a long-acting beta-agonist will be administered for at least 4 weeks. If no satisfactory response to this treatment is observed, an anti-leukotriene agent or in the next step systemic corticosteroid will be applied. Ineffective treatment with the above-mentioned medications will indicate an opportunity for a different underlying cause of BHR. The estimation the area under a ROC (receiver operating characteristic) curve will be used to determine the optimal cut-off point for the differentiation between asthma and alternate causes of a chronic cough.
It is expected to assess the frequency of bronchial hyperresponsiveness in subjects with a chronic cough, to confirm a correlation between the results of MCT and the sensitivity of cough reflex measured in capsaicin inhalation cough challenge. The investigation will probably determine a precise cut-off point for MCT which would allow discriminating asthma from other causes of a chronic cough.
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||The Usefulness of the Methacholine Challenge Test and Capsaicin Inhalation Cough Challenge in a Prediction of Response to Management in Adults With a Chronic Cough.|
|Actual Study Start Date :||September 30, 2016|
|Estimated Primary Completion Date :||September 30, 2021|
|Estimated Study Completion Date :||September 30, 2022|
- Other: Cough variant asthma treatment
Evaluation of the treatment response to inhaled corticosteroids, long-acting beta-agonists, montelukast, prednisone.
- The decrease of a cough after cough variant asthma therapy measured by Leicester Cough Questionnaire (LCQ). [ Time Frame: at least 4 weeks of treatment ]Increase in quality of life measured with LCQ min. 1.3 points.
- The decrease of a cough after cough variant asthma therapy measured by Visual Analogue Scale (VAS). [ Time Frame: at least 4 weeks of treatment ]Reduction of cough intensity measured by VAS: Reduction min. 20 mm in VAS
- The decrease of a cough after cough variant asthma therapy measured by the cough challenge. [ Time Frame: at least 4 weeks of treatment ]Increase capsaicin concentration causing causing two/five (C2/C5) cough episode in the cough challenge.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03363698
|Contact: Aleksandra M. Rybka, MD||+48 firstname.lastname@example.org|
|Department of Internal Medicine, Lung Diseases and Allergy Medical University of Warsaw||Recruiting|
|Warsaw, Mazowieckie, Poland, 02-097|
|Contact: Aleksandra M. Rybka, MD +48 225992957 email@example.com|